A cost effectiveness study establishing the impact and accuracy of implementing the NICE guidelines lowering plasma NTproBNP threshold in patients with clinically suspected heart failure at our institution

Webb, Jessica; Draper, Jane; Rua, Tiago; Yiu, Yee; Piper, Susan; Teall, Thomas; Fovargue, Lauren; Bolca, Elena; Jackson, Thomas; Claridge, Simon; Sieniewicz, Benjamin; Porter, Bradley; McDiarmid, Adam K; Rajani, Ronak; Kapetanakis, Stamatis; Rinaldi, Christopher Aldo; Razavi, Reza; McDonagh, Theresa A.; Carr‐White, Gerald

doi:10.1016/j.ijcard.2017.10.126

Cited by 1 publication

(1 citation statement)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies on health-care costs and implementation of health-care guidelines have been published for diseases such as cancer, 31 chronic kidney disease, 32 diabetes, 33 heart disease, [34][35][36][37][38][39] osteoporosis, 40 and tuberculosis. 41 These studies, however, evaluated guidelines that differ from DMD in terms of the complexity, intensity, and duration of implementation.…”

Section: Discussionmentioning

confidence: 99%

Direct costs of adhering to selected Duchenne muscular dystrophy Care Considerations: Estimates from a midwestern state

et al. 2022

View full text Add to dashboard Cite

Introduction/Aims The multidisciplinary Duchenne muscular dystrophy (DMD) Care Considerations were developed to standardize care and improve outcomes. We provide cumulative cost estimates for selected key preventive (ie, excluding new molecular therapies and acute care) elements of the care considerations in eight domains (neuromuscular, rehabilitation, respiratory, cardiac, orthopedic, gastrointestinal, endocrine, psychosocial management) independent of completeness of uptake or provision of nonpreventive care. Methods We used de‐identified insurance claims data from a large midwestern commercial health insurer during 2018. We used Current Procedural Terminology and national drug codes to extract unit costs for clinical encounters representing key preventive elements of the DMD Care Considerations. We projected per‐patient cumulative costs from ages 5 to 25 years for these elements by multiplying a schedule of recommended frequencies of preventive services by unit costs in 2018 US dollars. Results Assuming a diagnosis at age 5 years, independent ambulation until age 11, and survival until age 25, we estimated 670 billable clinical events. The 20‐year per‐patient cumulative cost was $174 701 with prednisone ($2.3 million with deflazacort) and an expected total of $12 643 ($29 194) for out‐of‐pocket expenses associated with those events and medications. Discussion Standardized monitoring of disease progression and treatments may reduce overall costs of illness. Costs associated with these services would be needed to quantify potential savings. Our approach demonstrates a method to estimate costs associated with implementation of preventive care schedules.

show abstract

Section: Discussionmentioning

confidence: 99%

Direct costs of adhering to selected Duchenne muscular dystrophy Care Considerations: Estimates from a midwestern state

et al. 2022

View full text Add to dashboard Cite

show abstract

A cost effectiveness study establishing the impact and accuracy of implementing the NICE guidelines lowering plasma NTproBNP threshold in patients with clinically suspected heart failure at our institution

Abstract: Applying the recent updated NICE guidelines to an unselected real world population increases the AUC but would have a significant economic impact and only identified one new patient with heart failure.

Cited by 1 publication

References 19 publications

Direct costs of adhering to selected Duchenne muscular dystrophy Care Considerations: Estimates from a midwestern state

Direct costs of adhering to selected Duchenne muscular dystrophy Care Considerations: Estimates from a midwestern state

Contact Info

Product

Resources

About